ei-1

EI-1 is an inhibitor of Hepatitis C virus entry.

Tei-1194 is a semi-synthetic penicillin derivative with broad-spectrum antibacterial activity in vitro.

LEI-101 is a potent, selective, and orally bioavailable cannabinoid CB2 receptor agonist, with a pEC50 of 8 for hCB2, and a pKi of less than 4 for hERG. LEI-101 is approximately 100-fold more potent in binding to CB2 receptors than to CB1 receptors. It has therapeutic potential in diseases associated with inflammation and or oxidative stress, including kidney disease [1] [2].

LEI-106, a novel potent sn-1 DAGLalpha inhibitor, blocks the hydrolysis of sn-1-oleoyl-2-AG, inhibits the hydrolysis of 2-AG by the monoacylglycerol lipase ABHD6.

EI1 (Ezh2 inhibitor) is a potent and selective EZH2 inhibitor with IC50 of 15 nM and 13 nM for EZH2 (WT) and EZH2 (Y641F), respectively.

PP1 (AGL 1872), a specific and effective Src inhibitor, is with IC50 for Lck Fyn is 5 nM 6 nM, respectively.